Dr. Guo Chaoshe joined our Group in October 2013 and has been the
vice president of the marketing department since July 2015 and our deputy general manager
since December 2020.
From July 2006 to November 2010, and from February 2011 to November 2013, he was a
fellow at the Boston Children’s Hospital, a teaching affiliate of Harvard Medical School in the
United States. From October 2013 to June 2015, he was the research and development director
of our Company.
In July 1999, Dr. Guo obtained a master’s degree in physiology from Chinese Academy
of Medical Sciences of Peking Union Medical College in the PRC. In
November 2003, he obtained a doctorate degree in biochemistry from the University of
Göttingen in Germany.

Dr. Yang Yi joined our Group in November 2016. He has been our chief
scientific officer since January 2020, and our deputy general manager since December 15,
2020.
Dr. Yang was a post-doctoral fellow at the Littman Lab of New York University from
2008 to 2014. Since July 2014, he has been a tenure-track assistant professor in the department
of microbiology and immunology within the College of Medicine in the Medical University of
South Carolina (MUSC). He then became the director of antibody discovery of our Company
from November 2016 to December 2019. He has been chief scientific officer since September
2018, and has been the director of drug research and development since January 2020.
Dr. Yang obtained a bachelor’s degree in biology in July 1999 and with a master’s degree
in microbiology in July 2002 from Fudan University (復旦大學) in the PRC. In May 2008, he
obtained a doctorate degree in immunology from the University of Connecticut in the United
States.

Ms. Zhu Yan joined our Group in December 2011 and has been the vice president since July 2015 and our deputy general manager since December 2020.
From August 1988 to March 1999, Ms. Zhu joined Shougang General Hospital as a physician. Her last positions there were deputy director and attending physician of its cardiovascular disease prevention and control Institute. She was recognized as an attending physician by the Beijing Intermediate Professional and Technology Qualification Evaluation Committee in November 1995 while she was working there. She was awarded the Third Prize for Ministry of Health Science and Technology Progress Award by the Chinese Academy of Medical Science Institute of Cardiovascular Diseases in June 1998. She was also awarded the Prize for Progress of Science and Technology of Beijing for the study on prevention and treatment of hypertension among the Shougang community by the Beijing People’s Government. Afterwards, she worked in various companies in the PRC. From March 2010 to October 2011, she was the director of the department of strategic development of Beijing Hyundai Gundam Biotechnology Co., Ltd.
Ms. Zhu obtained a bachelor’s degree in preventive healthcare from Harbin Medical
University in the PRC in July 1988. She obtained a master’s degree in business management from Tsinghua University in the PRC as recognized by the Academic Degree Evaluation Committee of Tsinghua University in January 2005.

Dr. Yu Zhaoxue joined our Group in April 2020 and has been our deputy general manager since December 2020.
Dr. Yu joined Emory University as a postdoctoral fellow in October 2000. He then joined Alexion Pharmaceutical Inc., a biopharmaceutical company listed on the NASDAQ (stock code: ALXN) from September 2006 to December 2016 as a senior scientist III. Since January 2017, he has been the director of the complement system department at Achillion Pharmaceutical Inc., a company delisted from NASDAQ. From October 2018 to March 2020, he worked at Gemini Therapeutics, Inc., a medicine company listed on the NASDAQ (stock code: GMTX). Dr. Yu obtained a bachelor’s degree in medicine in July 1987 and a master’s degree in anatomy in June 1992 from Hubei University of Medicine in the PRC. In July 2000, he obtained a doctorate degree in medicine from Zhongshan Medical University in the PRC.

Mr. Liu Bin has been our chief financial officer since May 2020.He was the financial controller at ABB Xi’an Power Capacitor Co., Ltd. from March 2003 to April 2007. He was the chief financial officer at Shiji Tianle Wholesale Asset Porfolio from June 2010 to January 2016,and also at Xinjiang Keda Julong Equity Investment Partnership. He was also the vice president of finance of Hitevision Co., Ltd. ,a company listed on the Shenzhen Stock Exchange (stock code: 002955), from December 2018 to December 2019.
Mr. Liu obtained a bachelor’s degree in applied mathematics in June 1990 from Huazhong University of Science and Technology in the PRC. He also obtained a Master of Science degree from the University of Akron in the United States in August 1995. In August 1998, he obtained a master’s degree in business administration from the Arizona State University in the United States and a master’s degree in international management from the Thunderbird School of Global Management (formerly known as the American Graduate School of International Management) in the United States.

Mr. Wang Yongliang joined our Group in July 2017. He has been our deputy general manager since July 2021 and our chief secretariat officer since December 2020. Mr. Wang worked at SinoChem Group from August 2010 to February 2014. From February 2014 to September 2015, he was a senior investment manager of China SDIC High-tech Industry Investment Corporation, formerly known as China High-tech Investment Group whose wholly-owned subsidiary HighTech Investment Development Co., Ltd. was an investor shareholder of our Company. He was also a senior investment manager, vice president and deputy investment director of Harvest Investment Management Co., Ltd. from October 2015 to July 2017. Since July 2017, he has served as an assistant to the chairman of the Board of our Company.
Mr. Wang was awarded a Bachelor of Science degree with chemistry as his major from Nankai University in the PRC in June 2007. In June 2010, he obtained a Master of Science degree with macromolecular chemistry and physics as his major from Nankai University in the PRC.

Dirui Li received his PhD from College of Veterinary Medicine, China Agricultural University in 2012 (majoring in veterinary biomedicine) and research focused on infection and Immunology & Recombinant Vaccines; Then he did postdoc research at China Agricultural University and Uppsala University, Sweden. In 2016, he returned to China to join Biocytogen Pharmaceuticals（Beijing）Co., Ltd, successively served as Senior Scientist of Gene Editing Department, Manager of Pharmacological Department and Senior Manager of SD Department, currently served as the head of Pharmacology Department（Beijing/Haimen）, and developed the pharmacological platform (biomarker, drug metabolism, toxicological pathology detection platform) for Pharmacology Department.

Dr. Zhang obtained a bachelor’s degree in biochemistry from Hebei Normal University
in the PRC in June 2004. In June 2011, she obtained a doctorate degree in
Chinese medicine from China Pharmaceutical University in the PRC. Now she is our executive Director and senior operation director of animal centre, and is primarily responsible for overseeing our Group’s operations and management and animal model business line. Dr. Zhang joined our Company in December 2009 and served as the head of the department of molecular biology till March 2012. From March 2012 to October 2015, Dr. Zhang was the marketing director of our Company. From September 2015 to July 2019, she was a supervisor of our Company. She has served as an executive Director of our Company since July 24, 2019.

Dr. Yao received his Ph.D. degree in Pharmaceutical Engineering from Tianjin University in 2012. His research interests include protein interactions, high-throughput screening, and mechanisms of antioxidant signaling pathways. In June 2012, he joined Biocytogen. He has led or participated in the development of EGE technology for efficient gene editing, the establishment of gene editing platform for cell lines, the promotion of laboratory automation, and the work related to the development and application of SUPCETM technology. Dr. Yao has nearly ten years of experience in gene editing technology development and animal model development. He is currently the Senior Director of Future Institute.

Dr. Chen Zhaorong has been our deputy general manager. He has also been the CEO and CMO of Eucure . Dr. Chen was the representative of Sanofi China and the vice president of GlaxoSmithKline China. He also worked as the chief medical officer of CASI Pharmaceuticals, Inc, a biopharmaceuticals company listed on NASDAQ (stock code: CASI). From November 2016 to December 2017, he served as the chief medical officer of Phagelux (Nanjing) Biotechnology Co., Ltd. He was also the chief medical officer of Chime Biologics (Wuhan) Co., Ltd, formerly known as Xikang (Wuhan) Biopharmaceutical Co., Ltd., from January 2018 to January 2020, and Shanghai Langyu Health Technology (Group) Co., Ltd.
Dr. Chen obtained a bachelor’s degree in medicine in August 1983 and a master’s degree
in pharmacology in October 1985 from Shandong Medical University (formerly known as Shandong Medical College) in the PRC. In May 1989, he obtained a doctorate degree in philosophy from the University of Adelaide in Australia.

Ms.Sabrina Wang joined our Group in October 2019. She has been our deputy general manager since December 2020, and the chief operation officer of Eucure (Beijing) since October 2019. From May 2004 to May 2012, Ms. Wang was a laboratory assistant, project coordinator, senior project coordinator, associate project manager, project manager, associate business development manager and business development manager of Q Squared Solutions (Beijing) Co., Ltd. She was also the Asia Regional Pre-Analytical Services and Investigator Manager at Q Squared Solutions (Singapore) Co., Ltd. between May 2012 and July 2013. From July 2013 to July 2014, she held the role of associate business development director at IQVIA China. From September 2014 to August 2018, she served at Paraxel China Co., Ltd. as she was the director of business development, head of business development in China, and senior director of portfolio management. From September 2018 to October 2019, she was the head of Biotech Delivery Unit at IQVIA China. Ms. Wang obtained a bachelor’s degree in medicine from Chongqing Medical University in the PRC of Chongqing Medical University in July 2003.

Dr. Li Zhihong joined our Group in March 2019. He has been the deputy general manager of our Company since December 2020, and our chief regulatory and strategy officer of the Eucure (Beijing) since March 2019. Dr. Li has clinical development and review experience in several therapeutics areas including oncology. He worked at Pfizer Inc., and was as staff fellow at Food and Drug Administration of the United States from May 2009 to December 2017.
Dr. Li obtained a bachelor’s degree and a master’s degree in pharmacy in July 1992 and
in June 1995 respectively from Beijing Medical University in the PRC. In March 2007, he obtained a doctor of philosophy degree from the University of Minnesota in the United States.

Dr. Lin Qingcong joined our Group in February 2018 and has been our deputy general manager since December 2020. He has also been serving as CEO of BIOCYTOGEN BOSTON CORP since February 1, 2018. He was a post-doctoral researcher at Albert Einstein College of Medicine from February 1999 to August 2001 and at Harvard Medical School from 2001 to 2002. From 2002 to 2005, he was director of gene modification laboratory at the Harvard-Partners Center for Genetics and Genomics. From 2005 to 2009, he was a senior scientist and principal scientist at the Global Biotherapeutic Technologies department of Wyeth Pharmaceutical Co Ltd (acquired by Pfizer Inc. in 2009). He also worked at the immune protein screening group of Pfizer Inc. between 2010 and 2013. From January 2014 to February 2018, he worked at Shenogen Pharma Group and his last position was senior vice president.
Dr. Lin obtained a Bachelor of Science degree in biology (cell biology) from Wuhan
University in the PRC in July 1984. He then obtained a Master of Science degree
from Wuhan University in the PRC in August 1987. In January 1999, he obtained a doctorate
degree in philosophy from the Albert Einstein College of Medicine in the United States.

Dr. Jin received his Bachelors and Ph.D. degrees from the Department of Virology and Molecular Biology atWuhan University. Dr. Jin performed Postdoctoral Research and served as a Research Assistant Professor at the University of Illinois. He also researched human embryonic stem cells at Advanced Cell Technology (ACT). In November 2011, he joined Biocytogen USA and served as the Vice President.